Do FADS1 variants reduce omega-3 conversion and increase reliance on EPA and DHA?

Genetic variations in the fatty acid desaturase 1 (FADS1) gene play a pivotal role in determining systemic levels of highly biologically active long-chain polyunsaturated fatty acids (LC-PUFAs).

Clinical and metabolic impact

• Impaired bioconversion: The FADS1 gene encodes the delta-5 desaturase (D5D) enzyme, which acts as the rate-limiting bottleneck in PUFA biosynthesis.
• Significant enzymatic reduction: Key single nucleotide polymorphisms (SNPs) such as rs174537, rs174547, and rs174546 directly alter D5D expression. Minor allele carriers (e.g., the C allele of rs174547 or the T allele of rs174537) exhibit a 40% to 60% reduction in endogenous LC-PUFA synthesis.
• Dietary dependency: Because conversion of plant-derived alpha-linolenic acid (ALA) to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) is compromised, these individuals cannot efficiently rely on precursor plant oils and have an increased, direct dependence on preformed dietary or supplemental EPA and DHA to maintain tissue sufficiency.

Mechanistic pathways

• D5D index shift: Enzyme activity is functionally tracked via the arachidonic acid to dihomo-gamma-linolenic acid (AA/DGLA) ratio, which serves as a proxy for in vivo D5D activity.
• Eicosanoid balance: Alterations in this ratio shift downstream lipid metabolism. A lower AA/DGLA ratio modulates the synthesis of pro-inflammatory AA-derived eicosanoids relative to less inflammatory DGLA-derived eicosanoids, altering the baseline inflammatory signaling cascade.

Bottom line

• Individuals with low-activity FADS1 variants exhibit a genetic bottleneck that restricts the conversion of plant-based essential fatty acids to EPA and DHA. To bypass this metabolic block and maintain optimal tissue status, these individuals require direct intake of preformed marine- or algae-derived omega-3s.